1. Chinese Medicine Meets Conventional Medicine in Targeting COVID-19 Pathophysiology, Complications and Comorbidities
   Shan-shan Wang et al, 2022, Chin. J. Integr. Med. CrossRef
2. Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high-risk elderly with COVID-19 infection: A retrospective study in an old age home in Hong Kong
   Timothy P. H. Lin et al, 2022, Front. Med. CrossRef
3. Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway
   Yanhui Zhu et al, 2022, Journal of Ethnopharmacology CrossRef
4. Recent advances in Chinese patent medicines entering the international market
   Bo Zhang et al, 2022, DD&T CrossRef
5. COVID-19 Therapeutic Potential of Natural Products
   Zhaoxuan Low et al, 2023, IJMS CrossRef
6. “Three medicines and three formulas” in COVID-19: from bench to bedside
   Guangxu Xiao et al, 2023 CrossRef
7. Salvia miltiorrhiza Bunge extract and Przewalskin ameliorate Bleomycin-induced pulmonary fibrosis by inhibition of apoptosis, oxidative stress and collagen deposition via the TGF-β1 pathway
   Mengnan Zeng et al, 2024, Phytomedicine CrossRef
8. Network-based pharmacology and UHPLC-Q-Exactive-Orbitrap-MS reveal Jinhua Qinggan granule's mechanism in reducing cellular inflammation in COVID-19
   Liping Qian et al, 2024, Front. Immunol. CrossRef